Abstract:

Breast cancer is the most common cancer in Chinese women. Endocrine therapy for hormone receptor-positive breast cancer has a good curative effect, but it can induce osteoporosis, which is a difficult problem that must be solved urgently in clinics. To prevent and treat endocrine therapy-related osteoporosis, clinical researchers have explored a number of measures. Modern medicines mainly include anti-bone absorbent agents, selective estrogen receptor modulators, and receptor activator of nuclear factor kappa B ligand (RANKL) monoclonal antibodies, which are used to treat osteoporosis by inhibiting osteoclast differentiation and maturation. Traditional Chinese medicine regulates bone metabolism by tonifying kidney as the foundation, soothing liver and invigorating spleen, and promoting blood circulation and dredging collaterals; it shows strong therapeutic potential. Early bone health assessment is the key in the prevention and treatment of endocrine therapy-related osteoporosis. Continuous innovation in assessment techniques offers promising prospects for its prevention and control. This paper focuses on the pathogenesis of osteoporosis associated with endocrine therapy for breast cancer, as well as the research progress of prevention and treatment of osteoporosis in modern medicines and traditional Chinese medicines, so as to contribute to its further study and better serve clinical practice.

Key words:

Breast cancer, Endocrine therapy, Osteoporosis, Traditional Chinese medicine, Progress

摘要：

乳腺癌是目前中国女性最常见的癌症。激素受体阳性乳腺癌的内分泌治疗取得了较好的疗效，但可诱发骨质疏松，是临床亟待解决的难题。针对内分泌治疗相关性骨质疏松，临床研究者探索出多种防治措施。现代医药主要包括抗骨吸收剂、选择性雌激素受体调节剂、核因子-κB受体活化因子配体（RANKL）单克隆抗体等，通过抑制破骨细胞分化和成熟治疗骨质疏松。中医药以补肾为根本，兼疏肝健脾、活血通络之法，调节骨代谢，也显示出较强的治疗潜力。早期骨骼健康评估是内分泌治疗相关性骨质疏松防治的关键。评估技术的不断革新为其防治提供了美好的前景。本文着重探讨了乳腺癌内分泌治疗相关性骨质疏松的发病机制以及现代医药和传统中医药的防治研究进展，旨在有助于其深入研究，从而更好地服务于临床实践。

关键词:

乳腺癌, 内分泌治疗, 骨质疏松, 中医中药, 进展